{"title":"Tezepelumab对严重未控制哮喘患者住院和急诊就诊的影响:来自Pathway 2b期试验的结果","authors":"J. Corren, Stephanie Chen, L. Callan, E. G. Gil","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2622","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"70 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial\",\"authors\":\"J. Corren, Stephanie Chen, L. Callan, E. G. Gil\",\"doi\":\"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2622\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":104393,\"journal\":{\"name\":\"B15. IMMUNOTHERAPY FOR LUNG DISEASE\",\"volume\":\"70 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B15. IMMUNOTHERAPY FOR LUNG DISEASE\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2622\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial